PharmaCyte Biotech announces Nasdaq uplisting and pricing of $15M public offering at $4.25/unit

PharmaCyte Biotech, Inc.

Common stock begins trading on Nasdaq Capital Market under PMCB on August 10, 2021.
Public offering of 3,529,412 units at $4.25 per unit (1 share + 1 warrant); gross proceeds ~$15M.
Warrants exercisable at $4.25, immediately, expire in 5 years; pre-funded warrants also offered.
H.C. Wainwright sole book-runner; underwriter granted 30-day option for up to 529,411 additional units.
Executive officers and directors subject to 90-day lock-up from prospectus supplement date.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.